Literature DB >> 3955913

Survival in idiopathic membranous glomerulonephritis.

E Honkanen.   

Abstract

Sixty-seven patients with idiopathic membranous glomerulonephritis (iMGN) were analyzed clinically. Their mean age was 39.3 years, and 47 (70%) of them were male. Fifty (74.6%) showed nephrotic syndrome (NS) initially and five (7.5%) had additionally chronic renal failure. Hypertension was present in 27%. During the follow-up (mean 6.7 years) renal death occurred in four patients 12-151 (mean 84.2) months after the diagnosis of iMGN. Four patients died of non-renal causes. The actuarial life-table survival at 5, 10 and 15 years was 94%, 83% and 69%, respectively. To some extent renal function deteriorated in 13 patients (19%). These patients were older (49.9 vs. 36.8 years, p less than 0.01) than those with preserved renal function, and many of them had serum creatinine levels of 125 mumol/l or more initially. Sex did not correlate with the development of renal insufficiency. Patients with slight proteinuria never showed loss of renal function. The retrospective comparison of survival in patients who did (N = 31) or did not (N = 19) receive corticosteroids and/or immunosuppressive drugs for the treatment of NS revealed no evident difference at 5 or 10 years. This clinical analysis emphasizes the fairly favorable outcome of patients with iMGN. Hence a reserved view must be taken when treatment with potentially dangerous agents is considered in a disease with unknown etiology and pathogenesis.

Entities:  

Mesh:

Year:  1986        PMID: 3955913

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  9 in total

Review 1.  Therapy of idiopathic membranous nephropathy.

Authors:  C Ponticelli; P Zucchelli; P Passerini
Journal:  Springer Semin Immunopathol       Date:  1987

Review 2.  Membranous nephropathy in childhood and its treatment.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1990-03       Impact factor: 3.714

Review 3.  Management of Membranous Nephropathy in Western Countries.

Authors:  Talal Alfaadhel; Daniel Cattran
Journal:  Kidney Dis (Basel)       Date:  2015-09-09

4.  Interstitial myofibroblasts: predictors of progression in membranous nephropathy.

Authors:  I S Roberts; C Burrows; J H Shanks; M Venning; L J McWilliam
Journal:  J Clin Pathol       Date:  1997-02       Impact factor: 3.411

5.  Lupus-like membranous nephropathy: Is it lupus or not?

Authors:  Ramin Sam; Amit Joshi; Sam James; Kuang-Yu Jen; Firouz Amani; Peter Hart; Melvin M Schwartz
Journal:  Clin Exp Nephrol       Date:  2014-07-04       Impact factor: 2.801

6.  Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy.

Authors:  Jicheng Lv; Wanyin Hou; Xujie Zhou; Gang Liu; Fude Zhou; Na Zhao; Ping Hou; Minghui Zhao; Hong Zhang
Journal:  J Am Soc Nephrol       Date:  2013-06-27       Impact factor: 10.121

7.  Management of adverse renal events related to alemtuzumab treatment in multiple sclerosis: a Belgian consensus.

Authors:  Ben Sprangers; D Decoo; D Dive; A Lysandropoulos; L Vanopdenbosch; C Bovy
Journal:  Acta Neurol Belg       Date:  2017-11-30       Impact factor: 2.396

8.  Clinical outcomes and effects of treatment in older patients with idiopathic membranous nephropathy.

Authors:  Yaeni Kim; Hye Eun Yoon; Byung Ha Chung; Bum Soon Choi; Cheol Whee Park; Chul Woo Yang; Yong-Soo Kim; Yu Ah Hong; Suk Young Kim; Yoon-Kyung Chang; Hyeon Seok Hwang
Journal:  Korean J Intern Med       Date:  2019-08-14       Impact factor: 2.884

9.  Chapter 7: Idiopathic membranous nephropathy.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.